Signals, Powered By EquityPandit
The US-based subsidiary of Lupin, Gavis Pharmaceuticals has received tentative approval from the USFDA for Azithromycin for oral suspension, an anti-bacterial drug, in the American market.
Lupin has said in a BSE filing that Gavis has received tentative approval for its Azithromycin for oral suspension USP from the United States Food and Drug Administration (FDA).
The company’s product is a generic version of Pfizer Inc’s Zithromax and has been indicated for mild to moderate infections caused by bacteria.
